View Item 

Show simple item record

Chemical dissociation of human awareness: focus on non-competitive NMDA receptor antagonists
dc.contributor.authorDomino, Edward F.en_US
dc.date.accessioned2010-04-14T14:04:46Z
dc.date.available2010-04-14T14:04:46Z
dc.date.issued1992en_US
dc.identifier.citationDomino, Edward (1992). "Chemical dissociation of human awareness: focus on non-competitive NMDA receptor antagonists." Journal of Psychopharmacology 6(3): 418-424. <http://hdl.handle.net/2027.42/68872>en_US
dc.identifier.issn0269-8811en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/68872
dc.description.abstractSince the mid-1950s the pharmaceutical industry has developed a number of chemicals, including phencyclidine, ketamine and related arylcyclohexylamines (PCE and TCP), dizocilpine (MK-801), N-allylnormetazocine [ NANM, (±)SKF-10,047], etoxadrol, dioxadrol and its enantiomers dexoxadrol and levoxadrol, which produce a constellation of unusual behavioral effects in animals and man. The compounds best studied in humans are phencyclidine and ketamine. They produce a remarkable dose-dependent dissociation of awareness. All of these substances are now known to be non-competitive antagonists of NMDA receptors of glutamic acid. They act in the NMDA receptor ion channel. One can conclude, on the basis of the effects observed with these agents, that glutamic acid and related excitatory amino acids are extremely important in the maintenance of human awareness.en_US
dc.format.extent3108 bytes
dc.format.extent616777 bytes
dc.format.mimetypetext/plain
dc.format.mimetypeapplication/pdf
dc.publisherSage Publicationsen_US
dc.subject.otherNMDA Receptor Antagonistsen_US
dc.subject.otherAwarenessen_US
dc.subject.otherDissociationen_US
dc.titleChemical dissociation of human awareness: focus on non-competitive NMDA receptor antagonistsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelPsychiatryen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Pharmacology, University of Michigan, Ann Arbor, MI 48109-0626, USAen_US
dc.identifier.pmidbaden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/68872/2/10.1177_026988119200600312.pdf
dc.identifier.doi10.1177/026988119200600312en_US
dc.identifier.sourceJournal of Psychopharmacologyen_US
dc.identifier.citedreferenceAlbin M.S., Bunegin L., Garcia C. (1990) Ketamine and postanesthetic emergence reactions. In Domino E F (ed.), Status of ketamine in anesthesiology. NPP Books, Ann Arbor, pp. 17-25en_US
dc.identifier.citedreferenceBerry S.C., Anis N.A., Lodge D. (1984) The effect of the dioxolanes on amino acid induced excitation in the mammalian spinal cord. Brain Res 307: 85-90en_US
dc.identifier.citedreferenceBrady K.T., Balster R.L., May E.L. (1982) Stereoisomers of N-allylnormetazocine: Phencyclidine-like behavioral effects in squirrel monkeys and rats. Science 215: 178-180en_US
dc.identifier.citedreferenceBurns R.S., Lerner S.E. (1981) The effects of phencyclidine in man: A review. In Domino E F (ed.), PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp. 449-470en_US
dc.identifier.citedreferenceCarlsson M., Carlsson A. (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia—implications for schizophrenia and Parkinson's disease. Trends Neuropsychol 13: 272-276en_US
dc.identifier.citedreferenceChen G. (1981) The neuropharmacology of phencyclidine. In Domino E F (ed.), PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp. 9-16en_US
dc.identifier.citedreferenceClineschmidt B.V., Martin G.E., Bunting P.R. (1982a) Anticonvulsant activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-amine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2: 123-134en_US
dc.identifier.citedreferenceClineschmidt B.V., Martin G.E., Bunting P.R., Papp N.L. (1982b) Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-amine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2: 135-145en_US
dc.identifier.citedreferenceClineschmidt B.V., Williams M., Witoslawski J.J., Bunting P.R., Risley E.A., Totaro J.A. (1982c) Restoration of shock-suppressed behavior by treatment with (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-amine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2: 147-163en_US
dc.identifier.citedreferenceCohen B.D., Rosenbaum G., Luby E.D., Gottlieb J.S., Yelen D. (1959) Comparison of Sernyl with other drugs. I. Attention, motor function and proprioception. Arch Gen Psychiatr 1: 651-656en_US
dc.identifier.citedreferenceCorssen G. (1990) Historical aspects of ketamine-first clinical experience. In Domino E F (ed.), Status of ketamine in anesthesiology. NPP Books, Ann Arbor, pp. 1-5en_US
dc.identifier.citedreferenceCorssen G., Domino E.F. (1966) Dissociative anesthesia: Further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 45: 29-40en_US
dc.identifier.citedreferenceDomino E.F., Chodoff P., Corssen G. (1965) Pharmacologic effects of CI-581, a new dissociative anesthetic in man. Clin Pharmacol Ther 6: 279-291en_US
dc.identifier.citedreferenceDomino E.F., Luby E.D. (1981) Abnormal mental states induced by phencyclidine as a model of schizophrenia. In Domino E F (ed.), PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp. 401-418en_US
dc.identifier.citedreferenceDomino E F, Kamenka J-M, eds (1988) Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arboren_US
dc.identifier.citedreferenceDundee J.W. (1990a) Early British experience with ketamine. In Domino E F (ed.), Status of ketamine in anesthesiology. NPP Books, Ann Arbor, pp. 7-10en_US
dc.identifier.citedreferenceDundee J.W. (1990b) The taming of ketamine. In Domino E F (ed.), Status of ketamine in anesthesiology. NPP Books, Ann Arbor, pp. 11-16en_US
dc.identifier.citedreferenceFauman M.A., Fauman B.J. (1981) Chronic phencyclidine (PCP) abuse: A psychiatric perspective. In Domino E F (ed.), PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp. 419-436en_US
dc.identifier.citedreferenceFoster N.L., Giordani B., Mellow A., Aronson S., Berent S. (1991) Memory effects of low-dose ketamine in Alzheimer's disease. Neurology 41: 214en_US
dc.identifier.citedreferenceFrederickson E.L., Longnecker D.E., Allen G.W. (1976) Clinical investigation of a new intravenous anesthetic— etoxadrol hydrochloride (C1-1848:U-37862A). Anesth Analg Curr Res 55: 335-339en_US
dc.identifier.citedreferenceGreifenstein F.E., De Vault M., Yoshitake J., Gajewski J.E. (1958) A study of 1-arylcyclohexylamine for anesthesia. Anesth Analg 37: 283-294en_US
dc.identifier.citedreferenceHampton R.Y., Medzihradsky F., Woods J.H., Dahlstrom P.J. (1982) Stereospecific binding of 3H-phencyclidine in brain membranes. Life Sci 30: 2147-2154en_US
dc.identifier.citedreferenceIversen L.L., Woodruff G.N., Kemp J.A., Foster A.C., Gill R., Wong E H F (1988) Pharmacology and neuroprotective effects of the NMDA antagonist MK-801. In Domino E F, J-M Kamenka (eds), Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp. 757-766en_US
dc.identifier.citedreferenceJavitt DC, Zukin S.R. (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatr 148: 1301-1308en_US
dc.identifier.citedreferenceJasinski D.R., Martin W.R., Sappira J.D. (1968) Progress report on the dependence-reducing properties of GPA-1657, profadol hydrochloride (CI-572), propiram fumarate (BAY-4503) and dexoxadrol. Reported to the 30th Meeting, Committee on Problems of Drug Dependence, National Research Council, Indianapolis INen_US
dc.identifier.citedreferenceJohnstone M., Evans V., Baigel J.R. (1959) Sernyl (CI-395) in clinical anesthesia. Br J Anaesth 31: 433-439en_US
dc.identifier.citedreferenceKamenka J-M, Domino E F, eds (1992) Multiple sigma and PCP ligands: mechanisms for neuromodulation and neuroprotection? NPP Books, Ann Arboren_US
dc.identifier.citedreferenceKeats A.S., Telford J. (1964) Narcotic antagonists as analgesics. In Gould R F (ed.), Clinical aspects, series 45: molecular modification in drug design, advances in chemistry. American Chemical Society, Washington, pp. 170-176en_US
dc.identifier.citedreferenceKemp J.A., Priestley T., Woodruff G. N (1986) MK-801, a novel orally-active anticonvulsant, is a potent non-competitive N-methyl-D-aspartate receptor antagonist. Br J Pharmacol Proc Suppl 89: 535Pen_US
dc.identifier.citedreferenceKoek W., Woods J.H. (1988a) Assessing directly observable behavioral effects of phencyclidine (PCP)-like drugs in pigeons, in rats, and in rhesus monkeys. In Domino E F, Kamenka J-M (eds), Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp. 493-509en_US
dc.identifier.citedreferenceKoek W., Woods J.H. (1988b) Correlations between phencyclidine-like activity and N-methyl-D-aspartate antagonism: Behavioral effects. In Domino E F, Kamenka J-M (eds), Sigma and phencyclidine-like compounds as molecular probes in biology. NPP Books, Ann Arbor, pp.357-372en_US
dc.identifier.citedreferenceLargent BL, Gundlach AL, Schneider SH (1986) Pharmacological and autoradiographical discrimination of sigma and phencyclidine receptor binding sites in brain with (+) [ 3H] SKF-10,047, (+) [3H] 3-PPP, and [3H] TCP. J Pharmacol Exp Ther 238: 739-748en_US
dc.identifier.citedreferenceLasagna L., Pearson J.W. (1965) Analgesic and psychotomimetic properties of dexoxadrol. Proc Soc Exp Biol Med 118: 352-354en_US
dc.identifier.citedreferenceLear E., Suntay R., Pallin IN, Chiron A.E. (1959) Cyclohexamine (CI-400): A new intravenous agent. Anesthesiology 20: 330-335en_US
dc.identifier.citedreferenceLodge D., Anis N.A., Berry S.C., Burton N.R. (1983) Arylcyclohexylamines selectively reduce excitation of mammalian neurones by aspartate-like amino acids. In Kamenka J-M, Domino E F, Geneste P (eds), Phencyclydine and related arylcylohexylamines: present and future applications. NPP Books, Ann Arbor, pp. 595-616en_US
dc.identifier.citedreferenceLuby E.D. (1981) Phencyclidine revisited. In Domino E F (ed.), PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp. 25-30en_US
dc.identifier.citedreferenceLuby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. (1959) Study of a new schizophrenomimetic drug— Sernyl. Arch Neurol Psychiatr 81: 363-369en_US
dc.identifier.citedreferenceLuby E.D., Gottlieb J.S., Cohen B.D., Rosenbaum G., Domino E.F. (1962) Model psychoses and schizophrenia. Am J Psychiatr 119: 61-67en_US
dc.identifier.citedreferenceMaddox V.H. (1981) The historical development of phencyclidine. In Domino E F (ed.) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp. 1-8en_US
dc.identifier.citedreferenceMartin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. (1976) The effects of morphine and nalorphinelike drugs in the non-dependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197: 517-532en_US
dc.identifier.citedreferenceMc Carthy D.A. (1981) History of the development of cataleptoid anesthetics of the phencyclidine type. In Domino E F (ed.), PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp. 17-23en_US
dc.identifier.citedreferenceMeyer J.S., Greifenstein F., De Vault M. (1959) A new drug causing symptoms of sensory deprivation: Neurological, electroencephalographic and pharmacologic effects of Sernyl. J Nerve Ment Dis 129: 54-61en_US
dc.identifier.citedreferenceMusacchio J.M. (1990) The psychotomimetic effects of opiates and the σ receptor. Neuropsychopharmacology 3: 191-200en_US
dc.identifier.citedreferenceØye I., Hustveit O., Maurset A., Ratti Mobert E., Paulsen O., Skoglund L.A. (1991) The chiral forms of ketamine as probes for NMDA receptor functions in human. In Kameyama T, Nabeshima T, Domino E F (eds), NMDA receptor related agents: biochemistry, pharmacology and behavior. NPP Books, Ann Arbor, pp. 381-390en_US
dc.identifier.citedreferenceReimherr F.W., Wood D.R., Wender P.H. (1986) The use of MK-801, a novel sympathomimetic, in adults with attention deficit disorder, residual type. Psychopharmacol Bull 22: 237-242en_US
dc.identifier.citedreferenceScholler K.L., Thies H., Wiemers K. (1960) Die Allgemeinanaesthesie mit Cyclohexylaminodrivaten, klinische Beobachtungen und elektrencephalographische Untersuchungen (General anesthesia with cyclohexylamine derivatives, clinical observations and electroencephalographic studies). Der Anaesthesist 9: 163-169en_US
dc.identifier.citedreferenceSimopoulos A.M., Pinto A., Babikow P.W., Curland A., Savage C. (1970) Psychotomimetic properties and therapeutic potentials of dexoxadrol in convalescing alcoholics. Disease Nerv Syst 31: 203-207en_US
dc.identifier.citedreferenceTroupin A.S., Mendius J.R., Cheng F., Risinger M. W (1986) MK-801. In Meldrum B S, Porter R J (eds), New anticonvulsant drugs. John Libbey, London, pp. 191-201en_US
dc.identifier.citedreferenceVaupel D.B. (1983) Naltrexone fails to antagonize the σ effects of PCP and SKF-10,047 in the dog. Eur J Pharmacol 92: 269-274en_US
dc.identifier.citedreferenceWilson R.D., Traber D.L., Barratt E., Creson D., Schmitt R., Allen C.R. (1970) Evaluation of CL-1848C: A new dissociative anesthetic in normal human volunteers. Anesth Analg Curr Res 49: 236-241en_US
dc.identifier.citedreferenceWilson R.D., Allen C.R., Creson D., Schmitt R., Barratt E., Traber D.L. (1973) Operant behavior and neurophysiological observations of normal human volunteers receiving CL-1848C, a new dissociative anesthetic. Tex Rep Biol Med 31: 239-248en_US
dc.identifier.citedreferenceWong E H F, Kemp J.A., Priestley T., Night A.R., Woodruff G.N., Iversen L.L. (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83: 7104-7108en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10.1177_026988119200600312.pdf
Size:
602.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.